Human Embryonic Stem Cell Therapy in Cerebral Palsy Children with Cortical Visual Impairment: A Case Series of 40 PatientsGeeta Shroff1* and Lopamudra Das2
- *Corresponding Author:
- Geeta Shroff
Nutech Mediworld, H-8, Green Park Extension
New Delhi-110016, India
Tel: +91 11 26565548
Fax: +91 11 46057841
E-mail: [email protected]
Received date: September 18, 2014; Accepted date: November 21, 2014; Published date: November 24, 2014
Citation: Shroff G, Das L (2014) Human Embryonic Stem Cell Therapy in Cerebral Palsy Children with Cortical Visual Impairment: A Case Series of 40 Patients. J Cell Sci Ther 5:189. doi: 10.4172/2157-7013.1000189
Copyright: © 2014 Shroff G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Use of human embryonic stem cells (hESCs) has been explored for treatment of cortical visual impairment (CVI) in children with cerebral palsy (CP).
Objectives: The study evaluated efficacy and safety of hESC therapy in 40 CP children with CVI. Methods: The study had four treatment phases (T1, T2, T3, and T4) separated by gap phases. Patients were evaluated for visual impairment using Nutech Functional Scores (NFS).
Results: Of 40 patients included in study, 8 had NFS level "1" (were blind/ had no perception of light); 16 had level"2" (perception of light); 10 had level "3" (could identify blurred images); and 6 had level "4" (could see objects up to a distance of 25 cm from the eye). After therapy, 27 patients gained normal vision; 10 patients could see objects 25 cm from the eye; 2 patients could see blurred images; and 1 had perception of light. Overall, 39 patients showed improvement in NFS by at least one level. In SPECT scan, 2 patients had normal perfusion, 18 had significant improvement and 3 had moderate improvement.
Conclusion: Use of hESC therapy in patients with CVI showed beneficial results for treatment of CVI in children with CP.